CAPAFOUR

CAPAFOUR

In 2021, Cantargia initiated a third clinical trial, the phase Ib study CAPAFOUR, to investigate nadunolimab (CAN04) in combination with the chemotherapy regimen FOLFIRINOX for first line treatment of metastatic pancreatic cancer (PDAC).

The primary endpoint is safety, and secondary endpoints include effects on biomarkers and antitumor activity. Biopsies will be collected before and during therapy with the aim to learn more about potential effects of the therapy on the tumor microenvironment.

A total of 18 patients have been enrolled in CAPAFOUR and recruitment ended in October 2022. Initial safety and efficacy data will be presented in H2 2023.

Read more about CAPAFOUR on ClinicalTrials.gov (NCT04990037).